The product is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype E.
<0.001 EU per 1 μg of the peptide by the LAL method
Equine Botulinum Neurotoxin E Immune FAB2
The product is indicted for use in documented or suspected exposure to botulinum toxin serotype E in adults and pediatric patients.
Examples of Clinical Use:
The product binds to botulinum toxin serotype E to prevent toxicity.
Mechanism of action:
Equine Botulinum Neurotoxin E Immune FAB2 is a mix of polyclonal antibodies for botulinum toxin type E. It binds to the toxin with high-affinity and prevents binding to ganglioside anchorage sites and membrane-bound receptors on cholinergic nerve terminals. This prevents internalization of the toxin into the cell and ultimately prevents it from exerting its toxic effects. Due to the long-lasting effects of botulinum toxin, the antibodies must be administered before symptoms present to prevent toxicity.
The discovery and development of Equine Botulinum Neurotoxin E Immune FAB2
Equine Botulinum Neurotoxin E Immune FAB2 (EQ0001) is a novel therapeutic antibody being developed for the treatment of botulism in horses. Botulism is a serious neurological disease caused by the neurotoxins produced by the bacterium Clostridium botulinum. Horses are particularly susceptible to botulism, and it can be fatal if left untreated. Currently, there is no specific treatment available for equine botulism. EQ0001 is a monoclonal antibody that binds specifically to the neurotoxin produced by Clostridium botulinum serotype E. Monoclonal antibodies are highly specific antibodies engineered to recognize and neutralize specific targets. The discovery and development of EQ0001 involved extensive research and characterization of the botulinum neurotoxin E and the generation of monoclonal antibodies against it. This process likely included the isolation of the neurotoxin, immunization of animals (such as horses) to produce an immune response, and subsequent generation and screening of antibody candidates.
The function of Equine Botulinum Neurotoxin E Immune FAB2
Equine Botulinum Neurotoxin E Immune FAB2 (EQ0001) is a purified antibody fragment that specifically targets and neutralizes the botulinum neurotoxin E (BoNT/E). Botulinum neurotoxins are produced by Clostridium botulinum bacteria and are among the most potent toxins known. BoNT/E specifically targets and inhibits the release of acetylcholine, a neurotransmitter responsible for muscle contraction, leading to muscle paralysis. EQ0001 works by binding to BoNT/E and preventing it from binding to its target receptors on nerve cells. This binding effectively neutralizes the toxin, preventing its harmful effects on nerve function. By neutralizing the toxin, EQ0001 helps to prevent the progression of botulism and provides potential therapeutic benefits. It is important to note that EQ0001 is an equine-derived immune Fab fragment, meaning it is derived from horses that have been immunized with BoNT/E antigens. The FAB2 designation refers to the fragment's binding specificity, indicating that it contains two antigen-binding regions. Overall, the function of EQ0001 is to neutralize the botulinum neurotoxin E and potentially provide a therapeutic intervention for botulism caused by BoNT/E.
Clinical application of Equine Botulinum Neurotoxin E Immune FAB2
The Equine Botulinum Neurotoxin E Immune FAB2 is a specific medication that is used in the treatment of botulism, a serious and potentially life-threatening illness caused by the botulinum neurotoxin E. Botulism is typically caused by ingesting food contaminated with the botulinum neurotoxin, but it can also occur through wounds or by inhaling the toxin. The toxin affects the nervous system, leading to muscle paralysis and potentially causing respiratory failure. Equine Botulinum Neurotoxin E Immune FAB2 works by neutralizing the botulinum neurotoxin E in the body. It is an equine-derived antitoxin that contains antibodies specifically targeting the toxin. When administered, the antibodies bind to the toxin and prevent it from causing further damage. The clinical application of Equine Botulinum Neurotoxin E Immune FAB2 is primarily in the treatment of confirmed or suspected cases of botulism caused by the neurotoxin E. It is usually given intravenously, and the dosage and duration of treatment depend on the severity of the illness and the individual patient's response. By neutralizing the toxin, Equine Botulinum Neurotoxin E Immune FAB2 can help to prevent further progression of the illness, alleviate symptoms, and improve patient outcomes. It is an essential component in the management of botulism and is often used in conjunction with supportive care, such as respiratory support and physical rehabilitation. It is important to note that Equine Botulinum Neurotoxin E Immune FAB2 is derived from horses and may carry risks of allergic reactions or other adverse effects. Therefore, it should be administered under the supervision of healthcare professionals experienced in its use and monitoring for potential complications.
For research use only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products
without prior written approval from Creative BioMart.
For more information on how our products could help advance your project, please contact us.